Enable Injections Receives First U.S. Food and Drug Administration (FDA) Approval
The FDA has approved the EMPAVELI Injector (enFuse®) for the subcutaneous delivery of Apellis’ EMPAVELI® (pegcetacoplan) […]
New Look, Same Mission – enFuse®
Enable Injections is excited to introduce the new look for the enFuse® lid. The new enFuse […]
Russell Pagano Joins Enable Injections as VP, Regulatory Affairs
Russell Pagano Joins Enable Injections as VP, Regulatory Affairs We are pleased to announce Russell Pagano, […]
Enable Injections Announces $215 Million Financing
New financing provides significant financial flexibility to propel growth efforts, benefitting patients, providers, and pharma partners […]
What Is Enable Injections’ Superpower?
The Enable team is made up of passionate, entrepreneurial, and driven people who are working with […]
Enable Injections: Our Story and Team Culture
About Enable Injections Enable Injections is a Cincinnati-based investigational-stage company developing and manufacturing novel on-body injection […]
Letter from Mike Hooven, CEO, Enable Injections
Letter from Mike Hooven 18 MAY 2020 The current state in which we now live is […]
New Press on enFuse®
Enable Injections is pleased to share several notable events this February, including a new published articles […]
enFuse® Featured in Forbes: This Pharma Startup Could Transform How Chronic Diseases Are Treated
Throughout 2019, SAP has helped to spread the Enable Injections story and the potential for the enFuse […]
Scaling for Success: Why Enable Injections Is the Earliest-Stage Adopter of SAP
Many of us have someone close to us who receives intravenous (IV) therapies at a hospital […]